Short–term Intensive Neoadjuvant Chemotherapy Improving 10–year Survival for Patients with Stage II and Operable Stage III Breast Cancer

REFERENCES

1. ↵
   1. Quiet CA.
   2. Ferguson DJ.
   3. Weichselbaum RR. et al.

   Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up. J Clin Oncol, 1995;13:1144.

   OpenUrlAbstract
2. ↵
   1. Zhang B,
   2. Cha YE,
   3. Zhang Q, et al.

   Combination therapy of locally advanced breast cancer. Chinese Journal of Clinical Oncology, 1997;24:138.

   OpenUrl
3. ↵
   1. Fisher B,
   2. Anderson S,
   3. Wickerham D, et al.

   Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophophamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol, 1997; 15:1858.

   OpenUrlAbstract/FREE Full Text
4. 1. Fisher B,
   2. Anderson S,
   3. DeCillis A, et al.

   Further evaluation of intensified and increased total dose of cyclophophamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol, 1999;17:3374.

   OpenUrlAbstract/FREE Full Text
5. 1. Henderson IC,
   2. Berry DA,
   3. Demetri GD, et al.

   Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node–positive primary breast cancer. J Clin Oncol, 2003;21:976.

   OpenUrlAbstract/FREE Full Text
6. 1. Estevez LG,
   2. Cuevas JM,
   3. Anton A, et al.

   Weekly docetaxel as neoadjuvant chemotherapy for stage and breast cancer: efficacy and correlation with biological marker in a phase, multicenter study. Clin Cancer Res, 2003;9:686.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Jackisch C,
   2. von Minckwitz G,
   3. Eidtmann H, et al.

   Dose–dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer, 2002;3:276.

   OpenUrlPubMed
8. ↵
   1. Harris EE,
   2. Schultz D,
   3. Bertsch H, et al.

   Ten–year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys, 2003;55:1200.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Cance WG,
   2. Carey LA,
   3. Calvo BF, et al.

   Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg, 2002; 236:295.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Stebbing JJ,
    2. Gaya A.

    The evidence-based use of induction chemotherapy in breast cancer. Breast Cancer, 2001;8:23.

    OpenUrlCrossRefPubMed
11. 1. Buchholz TA,
    2. Hunt KK,
    3. Whitman GJ, et al.

    Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer, 2003;98:1150.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Mamounas EP.

    Neoadjuvant chemotherapy for operable breast cancer: is this the future? Clin Breast Cancer, 2003; Suppl 1:S10.
13. 1. Pierga JY,
    2. Mouret E,
    3. Laurence V, et al.

    Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer, the role of clinical response. Eur J Cancer, 2003;39:1089.

    OpenUrlCrossRefPubMedWeb of Science
14. 1. Onnefoi H,
    2. Diebold–Berger S,
    3. Therasse P, et al.

    Locally advanced/inflammatory breast cancers treated with intensive epirubicin–based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5–year clinical outcome? Ann Oncol, 2003;14:406.

    OpenUrlCrossRefPubMedWeb of Science
15. 1. Wang J,
    2. Buchholz TA,
    3. Middleton LP, et al.

    Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer, 2002;94:3107.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Penault–Llorca F,
    2. Cayre A,
    3. Bouchet Mishellany F, et al.

    Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol, 2003;22: 1319.

    OpenUrlPubMedWeb of Science